대한소화기학회지 (The Korean Journal of Gastroenterology)

  • 제66권3호
  • /
  • Pages.150-153
  • /
  • 2015
  • /
  • 1598-9992(pISSN)
  • /
  • 2233-6869(eISSN)
대한소화기학회 (The Korean Society of Gastroenterology)
권호 표지
DOI QR코드

DOI QR Code

절제 불가능한 췌장암 항암치료의 최신 지견

Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer

  • 류지곤 (서울대학교 의과대학 내과학교실, 간연구소)
  • Ryu, Ji Kon (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine)
  • 발행 : 2015.09.25
⟨ 이전 논문 다음 논문 ⟩

초록

Pancreatic adenocarcinoma is one of the fatalist malignancies. A large proportion of patients are diagnosed with unresectable stage pancreatic cancer at the time of presentation. Gemcitabine is a standard chemotherapeutic agent since 1997, but survival benefit is not satisfactory. Recent clinical study proved that several new combination chemotherapy regimens are superior to gemcitabine single chemotherapy and extended overall survival. However, its prognosis still remains grim. Current research is taking a multidirectional approach in the hope of developing more effective treatments. This article reviews the major clinical trial data that is the basis for the current chemotherapy regimens used as first- and second-line treatments for advanced pancreatic adenocarcinoma. This article also reviews the current ongoing clinical trials, which include the use of molecular targeting agents and immune therapies.

키워드

참고문헌

  1. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413. https://doi.org/10.1200/JCO.1997.15.6.2403
  2. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82. https://doi.org/10.1186/1471-2407-8-82
  3. Sultana A, Tudur Smith C, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007;96:1183-1190. https://doi.org/10.1038/sj.bjc.6603719
  4. Herrmann R, Bodoky G, Ruhstaller T, et al; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-2217. https://doi.org/10.1200/JCO.2006.09.0886
  5. Sato N, Fukushima N, Maehara N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003;22:5021-5030. https://doi.org/10.1038/sj.onc.1206807
  6. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-1703. https://doi.org/10.1056/NEJMoa1304369
  7. Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol 2014;15:829-840. https://doi.org/10.1016/S1470-2045(14)70236-0
  8. Conroy T, Desseigne F, Ychou M, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825. https://doi.org/10.1056/NEJMoa1011923
  9. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013;31:1640-1648. https://doi.org/10.1200/JCO.2012.43.3680
  10. Moore MJ, Goldstein D, Hamm J, et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966. https://doi.org/10.1200/JCO.2006.07.9525
  11. Van Cutsem E, Li CP, Nowara E, et al. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Br J Cancer 2014;111:2067-2075. https://doi.org/10.1038/bjc.2014.494
  12. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605-3610. https://doi.org/10.1200/JCO.2009.25.7550
  13. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617-3622. https://doi.org/10.1200/JCO.2010.28.1386
  14. Kindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011;12:256-262. https://doi.org/10.1016/S1470-2045(11)70004-3
  15. Gonçalves A, Gilabert M, François E, et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012;23:2799-2805. https://doi.org/10.1093/annonc/mds135
  16. Rougier P, Riess H, Manges R, et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer 2013;49:2633-2642. https://doi.org/10.1016/j.ejca.2013.04.002
  17. Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014;32:2423-2429. https://doi.org/10.1200/JCO.2013.53.6995
  18. Bayoglu IV, Varol U, Yildiz I, et al. Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer. Asian Pac J Cancer Prev 2014;15:7119-7123. https://doi.org/10.7314/APJCP.2014.15.17.7119
  19. Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011;80:301-306. https://doi.org/10.1159/000329803
  20. Lee MG, Lee SH, Lee SJ, et al. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second- line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Chemotherapy 2013;59:273-279. https://doi.org/10.1159/000356158
  21. Teague A, Lim KH, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol 2015;7:68-84. https://doi.org/10.1177/1758834014564775

피인용 문헌

  1. The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity vol.32, pp.11, 2016, https://doi.org/10.1080/03007995.2016.1211522
  2. 췌장암 한의 임상진료지침 개발 예비 연구 vol.22, pp.1, 2015, https://doi.org/10.15432/jkto.2017.22.1.001
  3. 췌장암에 대한 국내 한의학 연구 동향 고찰 - 국내 한의학 논문을 중심으로 - vol.40, pp.1, 2015, https://doi.org/10.22246/jikm.2019.40.1.70
  4. The Effect of Nutrition Intervention with Oral Nutritional Supplements on Pancreatic and Bile Duct Cancer Patients Undergoing Chemotherapy vol.11, pp.5, 2015, https://doi.org/10.3390/nu11051145